(6) In parallel, early explorations employing experimental frameworks have posited that Ipamorelin may potentially manifest actions akin to those observed with Tesamorelin in relation to skeletal muscle and bone structures
CJC-1295 without DAC (Mod GRF 1-29) has a 25 to 30-minute half-life and is dosed at 100 to 300 mcg one to three times daily
Ipamorelin Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin
Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3] It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4] Ipamorelin significantly increases plasma growth hormone (GH).[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.[3] Ipamorelin Peptide is under active investigation in a number of cell culture and animal models
It could help men with things like getting an erection, and may also enhance women's sexual function, but it is not FDA-approved for this use
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study
